2nd Quarter - Report

W STRATEGIES, LLC for ASTRAZENECA PHARMACEUTICALS LP

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Monitoring issues related to S. 2360, H.R. 4679: Stop Corporate Inversions Act of 2014 in the context of corporate acquisition activity.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4679 (113th), S. 2360 (113th)

Health Issues HCR

Education about access to therapies for children at risk of developing RSV(Respiratory Syncytial Virus), specifically with respect to guidelines by the American Academy of Pediatrics (AAP). Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.